<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705510</url>
  </required_header>
  <id_info>
    <org_study_id>154/2551(EC1)</org_study_id>
    <nct_id>NCT00705510</nct_id>
  </id_info>
  <brief_title>Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction</brief_title>
  <official_title>Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of 0.05% cyclosporine ophthalmic emulsion (Restasis® , Allergan)
      versus an artificial tears alone in patients with meibomian gland dysfunction that have
      abnormal tear quality and quantity by subjective symptoms and signs including tear breakup
      time
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Meibomian gland dysfunction patients will divide into 2 groups. One group will have 0.05%
      cyclosporine opthalmic emulsion and the other will have non-preservative artificial tear
      twice daily, compare the result in 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NTBUT</measure>
    <time_frame>0,1,2,3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OSDI score, FTBUT, lid inflammation, meibomian gland secretion and expressibility, bulbar and tarsal conjunctival injection,fluorescein staining, rose bengal staining</measure>
    <time_frame>0,1,2,3 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.05% cyclosporin eye drop</intervention_name>
    <description>use the medication twice daily for 3 months</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Restasis eye drop, Cellufresh eye drop</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, of legal age of consent

          -  Patient has a diagnosis of meibomian gland dysfunction with at least 1 symptom as the
             following; ocular burning, ocular discomfort, and grittiness

          -  Had a slit-lamp diagnosis of meibomian gland dysfunction based on the presence of one
             of the following

               -  meibomian gland inflammation by lid margin or tarsal erythema, bulbar conjunctiva
                  hyperemia, telangiectasia or thickening irregularity of the eyelid margins

               -  meibomian gland orifice inclusion (plugging) or abnormal of secretion

          -  Non-invasive tear break up time (NTBUT) with Tear scope Plus(Keeler, Windsor, UK) ≤ 8
             seconds

          -  Ability to follow study instruction and likely to complete all required visits

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  Patients with severe ocular disease from Steven Johnson syndrome burn, limbal
             deficiency

          -  Patients used cyclosporine within past 1 year

          -  Patients used oral cyclosporine or anticholinergic drug within past 2 months

          -  Patients with HIV or autoimmune disease

          -  Patients with active ocular infections and patients with a history of herpes keratitis

          -  Patients with known or suspected hypersensitivity to any of the ingredients in the
             formula (cyclosporine, glycerin, castor oil, polysorbate 80, carbomer 1342)

          -  Female patients are pregnant or nursing

          -  Patients who wear contact lenses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pinnita Prabhasawat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Siriraj H, Mahidol U</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology; Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2008</study_first_posted>
  <last_update_submitted>November 8, 2010</last_update_submitted>
  <last_update_submitted_qc>November 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pinnita Prabhasawat</name_title>
    <organization>Department of Ophthalmology; Siriraj Hospital</organization>
  </responsible_party>
  <keyword>Cyclosporine</keyword>
  <keyword>Unstable tear film</keyword>
  <keyword>Meibomian gland</keyword>
  <keyword>Meibomian gland dysfunction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

